# GQ1005

Source: https://onco.cc/drugs/gq1005/  
OnCo record `gq1005` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.

## Summary

GQ1005 is an antibody-drug conjugate developed by GeneQuantum Healthcare (Suzhou). Its target is HER2 (the sponsor names HER2). The sponsor states: A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673029 (A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer), in HER2-positive breast cancer. The largest, NCT07673029, plans to enrol 228 participants with primary completion expected 2027-01-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload.

## Sources

- ClinicalTrials.gov: trials of GQ1005: https://clinicaltrials.gov/search?intr=GQ1005
- Sponsor page: https://www.genequantum.com/pipeline

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [GeneQuantum Healthcare (Suzhou)](https://onco.cc/companies/genequantum-healthcare-suzhou/)
- trials: [A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer](https://onco.cc/trials/nct07673029/)

---
JSON: https://onco.cc/api/v1/entities/gq1005.json